In team with renowned physicians, immunologists, cancer biologists and molecular modelling colleagues sitting in different continents and those extraterrestrial AI nerds situated somewhere on the west coast I currently focus on developing small molecule based immunotherapeutics for treatment of high-risk malignancies such as but not limited to:
• Ovarian cancer
• Neuroblastoma
• Medulloblastoma
• Pancreatic cancer
• Melanoma
• Colorectal cancer
Complexities of drug-discovery commerce aside, small molecule based immunotherapeutics can be a viable alternative or a great complementary armamentarium to antibody based immunotherapies for treatment of high-risk malignancies or diseases.